Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DexCom, Inc. (DXCM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q when filed. Dexcom is listed on the Nasdaq Stock Market under the symbol DXCM, and its SEC filings offer detailed information on financial performance, governance, and material events related to its glucose biosensing and continuous glucose monitoring (CGM) business.
Recent Form 8-K filings illustrate how Dexcom uses SEC reports to communicate key developments. For example, the company has filed 8-Ks to furnish quarterly financial results, including revenue by geography and product component, and to describe leadership transitions such as the appointment of Jacob S. Leach as President and Chief Executive Officer and the appointment of Dr. Euan Ashley to the Board of Directors. These filings also document changes in board size, committee assignments, and executive roles.
Dexcom’s periodic reports, including 10-K and 10-Q filings when available, typically contain audited financial statements, discussions of sensor and hardware revenue, descriptions of its CGM and biosensing operations, and risk factor disclosures. Investors can also review sections on research and development spending, capital structure, and non-GAAP performance metrics that the company discusses alongside GAAP results in its earnings-related 8-Ks.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, margin commentary, governance updates, and other material items. Users can also monitor items related to director and executive appointments or departures, and other reportable events under Form 8-K. This page is a central resource for analyzing Dexcom’s regulatory history and for tracking how financial and governance information evolves over time.
Dexcom, Inc. (DXCM) — Initial insider ownership filing. Director Euan Ashley filed a Form 3 reporting no securities beneficially owned as of 10/24/2025. The filing is made by one reporting person and marks the initial statement of holdings for this insider role. A Power of Attorney (Exhibit 24) authorized the signature by an attorney-in-fact.
Dexcom expanded its Board and added new expertise. On October 24, 2025, the Board increased its size to ten directors and appointed Dr. Euan Ashley as a director, effective immediately, with a term expiring at the 2026 annual meeting. He joins the Nominating and Governance Committee and the Technology Committee; Kyle Malady steps down from the Nominating Committee and remains Technology Committee chair.
The Board also approved increasing the Board to eleven directors effective January 1, 2026, and confirmed the previously announced appointment of Jacob S. Leach effective that date, contingent on continued service. Dr. Ashley was deemed an independent director and received an initial $500,000 RSU grant vesting over three years, and will be eligible for an annual $345,000 RSU grant around the 2026 annual meeting; non‑employee director awards accelerate upon a change in control.
DexCom, Inc. announced that its Chief Executive Officer and Chairman, Kevin R. Sayer, has taken a temporary medical leave of absence effective September 14, 2025. To ensure continuity, the Board appointed Jacob S. Leach, the company’s President and Chief Operating Officer, to serve as interim principal executive officer while retaining his current responsibilities.
The Board also named Mark Foletta, the Lead Independent Director, as interim chairman of the Board. Neither Mr. Leach nor Mr. Foletta will receive additional compensation for these interim roles. The company states there is no special arrangement under which Mr. Leach was selected, no family relationships between him and other directors or executives, and no related-party transactions involving him that require disclosure.
Kyle Malady, a director of DexCom, Inc. (DXCM), reported a sale of common stock executed on 09/05/2025 under a previously adopted 10b5-1 trading plan. The Form 4 shows 667 shares were sold at $80.86 per share pursuant to the 10b5-1 plan adopted on 06/06/2025 to allow orderly dispositions. After the reported sale, Mr. Malady beneficially owned 22,667 shares, which include 5,192 unvested restricted stock units granted on 05/08/2025 that vest on the earlier of the one-year anniversary of the grant or DexCom’s 2026 Annual Meeting of Stockholders.
Sadie Stern, EVP and Chief HR Officer of DexCom, Inc. (DXCM), reported a sale of common stock under a pre-established plan. On 09/04/2025 Ms. Stern disposed of 1,466 shares at $80.00 per share pursuant to a 10b5-1 trading plan adopted on 02/20/2025 to allow orderly dispositions. After the reported sale she beneficially owns 105,223 shares in total. That total includes 74,450 unvested restricted stock units with detailed vesting: 29,922 RSUs granted 03/08/2025 vesting through 03/08/2028; 22,798 RSUs granted 03/08/2025 vesting through 03/08/2027; 14,474 RSUs granted 03/08/2024 vesting through 03/08/2027; and 7,256 RSUs granted 03/08/2023 vesting through 03/08/2026. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
DexCom insider notification: A person affiliated with DexCom, Inc. (DXCM) indicated a proposed sale of 667 common shares through Fidelity Brokerage Services with an aggregate market value of $53,933.62. The filing lists approximately 392,155,265 shares outstanding and an approximate sale date of 09/05/2025. The securities were acquired on 05/18/2024 via restricted stock vesting and paid as compensation. The filer reports no securities sold in the past three months and makes the Rule 144 representation that they are not aware of undisclosed material adverse information about the issuer.
DexCom Form 144 summary: This notice reports proposed sales of 1,466 shares of DexCom common stock to be executed through Morgan Stanley Smith Barney LLC on 09/04/2025 on NASDAQ, with an aggregate market value listed at $117,280.00. The filings show the same filer, Sadie Stern, sold 1,466 shares on 07/28/2025 for $130,459.34 and 1,466 shares on 06/26/2025 for $124,697.96 during the past three months. The securities to be sold were originally acquired as restricted stock from the issuer on 12/15/2023 (978 shares) and 11/19/2023 (488 shares). The filer affirms no undisclosed material adverse information.
DexCom insider sale under 10b5-1 plan: Sylvain Jereme M., Executive Vice President and Chief Financial Officer of DexCom (DXCM), reported the sale of 4,824 shares of DexCom common stock on 09/02/2025 at an average price of $74.17 per share. The filing states the sales were made pursuant to a 10b5-1 trading plan adopted on May 27, 2025 to allow orderly dispositions. After the reported disposition, Mr. Sylvain beneficially owns 118,657 shares, which include 83,328 unvested restricted stock units with scheduled vesting through March 8, 2028.
Form 144 filed for DexCom, Inc. (DXCM) proposing the sale of 4,824 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ at an aggregate market value of $357,796.08. The filing lists acquisition details for the shares: 3,464 shares received as restricted stock on 03/08/2023, 696 shares acquired via an employee stock purchase plan on 08/30/2019 (cash), and 664 shares from an employee stock purchase plan on 02/28/2020 (cash). The filer states there have been no securities sold in the past three months for the account and affirms no undisclosed material adverse information. The notice identifies the broker and gives the number of shares outstanding as 392,155,265.
DexCom insider sale under pre-established plan; small number of shares sold. Michael Jon Brown, EVP and Chief Legal Officer of DexCom (DXCM), sold 500 shares of common stock on 08/15/2025 at a reported price of $80.29 per share. The sale was executed pursuant to a 10b5-1 trading plan adopted on 02/21/2025, which the filing states allows for orderly dispositions of his shares.
After the reported sale Mr. Brown beneficially owned 94,102 shares. The filing discloses that 86,490 of those shares are unvested restricted stock units, detailed by grant dates and vesting schedules (grants from 2022–2025 with vesting through March 8, 2028). The form is signed by an attorney-in-fact on 08/18/2025.